Mitiglinide (calcium)

$60$194

Products Details

Product Description

– Mitiglinide Calcium (KAD-1229 anhydrous), an insulinotropic agent, is an ATP-sensitive K+ (KATP) channel antagonist. Mitiglinide Calcium is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide Calcium can be used for the research of type 2 diabetes[1][2].

Web ID

– HY-17398

Storage Temperature

– 4°C (Powder, sealed storage, away from moisture)

Shipping

– Room Temperature

Applications

– Metabolism-protein/nucleotide metabolism

Molecular Formula

– C19H24NO3.1/2Ca

References

– [1]Y Sunaga, et al. The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channels and insulin secretion: comparison with the sulfonylureas and nateglinide. Eur J Pharmacol. 2001 Nov 9;431(1):119-25.|[2]Kiyoshi Ichikawa, et al. Effect of KAD-1229, a novel hypoglycaemic agent, on plasma glucose levels after meal load in type 2 diabetic rats. Clin Exp Pharmacol Physiol. May-Jun 2002;29(5-6):423-7.

CAS Number

– 145525-41-3

Molecular Weight

– 334.44

Compound Purity

– 98.7

SMILES

– O=C([O-])[C@H](CC(N1C[C@](CCCC2)([H])[C@]2([H])C1)=O)CC3=CC=CC=C3.[0.5Ca2+]

Clinical Information

– Launched

Research Area

– Metabolic Disease

Solubility

– DMSO : 5 mg/mL (ultrasonic)

Target

– Potassium Channel

Pathway

– Membrane Transporter/Ion Channel

Product type

– Reference compound

Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.

My Cart
Close Wishlist
Close Recently Viewed
Categories

Please fill out this form to request the file. We will send it to your Email address shortly. Thanks.

Please enable JavaScript in your browser to complete this form.

=

Please fill out this form to request the pricing.
We will send it to your email address shortly.
Thanks.

Please enable JavaScript in your browser to complete this form.

=